Myasthenia Gravis trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Myasthenia Gravis. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by monthNo Myasthenia Gravis study has a primary completion filed in the next 180 days. The registered pipeline below carries no window, so it still shows what is there.
Every registered study in Myasthenia Gravis
most recently updated first22 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | Amgen | $229.9B | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)NCT06987539Maximum Observed Concentration (Cmax) of Inebilizumab | Phase 2 | Recruiting | Drug: Inebilizumab | Generalized Myasthenia Gravis | 15 | 2026-07-21 | 2030-03-13 | in 1,301 d | 2026-08-19 |
| RNAC | Cartesian Therapeutics | $278M | Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)NCT04146051Proportion of patients with MG Composite improvement of ≥5 points. | Phase 2 | Active, not recruiting | Drug: Descartes-08 | Myasthenia Gravis, Generalized | 30 | 2019-12-04 | 2026-01-05actual | — | 2026-08-14 |
| AZN | AstraZeneca | — | Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia GravisNCT06909253observationalChange from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score | — | Recruiting | Drug: Ravulizumab | Myasthenia Gravis, Generalized | 50 | 2025-05-15 | 2029-12-31 | in 1,229 d | 2026-08-14 |
| CABA | Cabaletta Bio | $493M | RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia GravisNCT06359041To evaluate incidence and severity of adverse events (AEs) | Phase 1/2 | Recruiting | Biological: CABA-201, CABA-201 | Generalized Myasthenia Gravis (gMG) | 24 | 2024-12-17 | Sep 2029 | ≤ 1,137 d | 2026-08-13 |
| AZN | AstraZeneca | — | Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in RussiaNCT07247279observationalAge at baseline (years) | — | Recruiting | — | Rare Diseases, Generalized Myasthenia Gravis (gMG) | 450 | 2025-12-23 | 2029-12-31 | in 1,229 d | 2026-08-12 |
| VRTX | Vertex Pharmaceuticals Incorporated | $133.9B | A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisNCT07501702Percent change in Total Immunoglobulin G (IgG) | Phase 2 | Recruiting | Drug: Povetacicept, Placebo | Myasthenia Gravis, Generalized | 30 | 2026-05-13 | 2029-03-02 | in 925 d | 2026-08-03 |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.0B | Study of Aritinercept in Patients With Generalized Myasthenia GravisNCT07596901To assess the safety and tolerability of aritinercept: Incidence of treatment-emergent adverse events | Phase 1/2 | Recruiting | Drug: Aritinercept · Other: Placebo | Myasthenia Gravis, Generalized | 81 | 2026-04-22 | 2029-03-02 | in 925 d | 2026-08-03 |
| KYTX | Kyverna Therapeutics | $526M | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia GravisNCT06193889Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 2) | Phase 2/3 | Recruiting | Drug: Standard of Care Treatment, Standard lymphodepletion regimen · Biological: KYV-101 | Myasthenia Gravis, Generalized Myasthenia Gravis | 66 | 2024-08-28 | Sep 2027 | ≤ 406 d | 2026-07-29 |
| DNTH | Dianthus Therapeutics | $6.5B | A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)NCT06282159Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) | Phase 2 | Active, not recruiting | Drug: Claseprubart, Placebo | Myasthenia Gravis, Generalized | 65 | 2024-02-23 | 2025-07-28actual | — | 2026-07-27 |
| TGTX | TG Therapeutics, Inc. | $7.7B | A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)NCT07673744Time to Onset of a Clinical Worsening Event | Phase 2 | Recruiting | Drug: Ublituximab, Placebo | Myasthenia Gravis | 120 | 2026-07-30 | 2028-07-01 | in 681 d | 2026-07-17 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia GravisNCT05070858Change in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score | Phase 3 | Active, not recruiting | Drug: Pozelimab + Cemdisiran, Cemdisiran, Pozelimab · Other: Placebo | Generalized Myasthenia Gravis | 288 | 2021-12-14 | 2025-07-08actual | — | 2026-07-08 |
| DNTH | Dianthus Therapeutics | $6.5B | A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)NCT07647510Change from Baseline to Week 17 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score | Phase 3 | Recruiting | Drug: Claseprubart, Placebo · Combination product: Claseprubart, Placebo | Myasthenia Gravis, Generalized | 195 | Jul 2026 | Dec 2028 | ≤ 864 d | 2026-07-08 |
| VOR | Vor Biopharma | $1.4B | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)NCT06456580Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score at Week 24 | Phase 3 | Recruiting | Biological: Telitacicept · Drug: Placebo | Generalized Myasthenia Gravis | 180 | 2024-07-17 | May 2027 | ≤ 284 d | 2026-06-18 |
| AZN | AstraZeneca | — | A Study in Patients With Myasthenia Gravis in ChinaNCT06700616observationalClinical outcome | — | Active, not recruiting | — | Myasthenia Gravis | 1,199 | 2024-09-26 | 2027-12-30 | in 497 d | 2026-06-11 |
| AMGN | Amgen | $229.9B | Myasthenia Gravis Inebilizumab TrialNCT04524273results2026-03-10Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population | Phase 3 | Active, not recruiting | Drug: inebilizumab, IV Placebo | Myasthenia Gravis | 238 | 2020-10-15 | 2024-05-28actual | — | 2026-05-15 |
| ISRG | Intuitive Surgical | $138.2B | SP Thoracic IDE StudyNCT05150210results2025-12-23Rate of Conversion | Not applicable | Active, not recruiting | Device: Robotic-Assisted Surgery | Primary Lung Cancer, Benign Lung Disease, Thymoma, Myasthenia Gravis | 32 | 2022-07-20 | 2023-06-16actual | — | 2025-12-23 |
| SNY | Sanofi | — | Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia GravisNCT05132569results2024-04-08DB Period: Change From Baseline in Myasthenia Gravis-activities of Daily Living (MG-ADL) Total Score at Week 26 | Phase 3 | Terminatedsponsor's stated reason: For strategic reasons the Tolebrutinib MG study has been terminated | Drug: Tolebrutininb, Placebo | Myasthenia Gravis | 6 | 2021-12-03 | 2023-02-21actual | — | 2025-09-09 |
| CPRX | Catalyst Pharmaceuticals, Inc. | $3.9B | Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MGNCT03304054results2021-08-13Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test Results | Phase 3 | Completed | Drug: Amifampridine Phosphate, Placebo Oral Tablet | Myasthenia Gravis, Generalized | 93 | 2018-04-18 | 2020-01-31actual | — | 2024-03-12 |
| CYTK | Cytokinetics | $10.6B | Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia GravisNCT01268280Quantitative Myasthenia Gravis score (QMG) | Phase 2 | Terminatedsponsor's stated reason: Closed after complete treatment of 32 patients after 21 months' recruitment. | Drug: Placebo, 250 mg CK-2017357, 500 mg CK-2017357 | Myasthenia Gravis | 32 | Dec 2010 | Oct 2012actual | — | 2019-09-24 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia GravisNCT01325571Change from baseline in quantitative myasthenia gravis (QMG) score for disease severity | Phase 3 | Completed | Drug: Tacrolimus capsule, Placebo | Myasthenia Gravis | 83 | Mar 2011 | May 2014actual | — | 2016-03-09 |
| 4503.T | Astellas Pharma Inc | $26.0B | FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) PatientsNCT00309088Mean dose of steroid to maintain minimal manifestation(MM)[The dose of steroid should be decreased by the rate of 5mg/alternate day/ 4 weeks after the initiation of tacrolimus or placebo treatment as far as the MM state should be maintained.] | Phase 3 | Completed | Drug: tacrolimus, placebo | Myasthenia Gravis | 80 | Apr 2006 | Jun 2008actual | — | 2014-08-25 |
| 4503.T | Astellas Pharma Inc | $26.0B | An Open Study for Steroid Resistant, Non-Thymectomized MG PatientsNCT00309101Improvement of clinical symptoms | Phase 3 | Completed | Drug: tacrolimus | Myasthenia Gravis | 11 | Feb 2006 | Feb 2009actual | — | 2009-06-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Myasthenia Gravis is matched — 4 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Myasthenia Gravis
- Myasthenia Gravis, Generalized
- Generalized Myasthenia Gravis
- Generalized Myasthenia Gravis (gMG)
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Myasthenia Gravis” (a text search, wider than this page)